Pricing Log in Create free account

Novavax, Inc. (NVAX) vs Pharvaris N.V. (PHVS)

Novavax, Inc. and Pharvaris N.V. are both Biotechnology companies. Novavax, Inc. and Pharvaris N.V. are of similar size ($2.1B and $2.1B). Pharvaris N.V. has the higher net margin (0.00% vs −59.9%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Novavax, Inc. leads on 7 and Pharvaris N.V. on 5.

Valuation

Metric NVAX PHVS Biotechnology median
P/E n/m n/m 8.50
P/S 4.48 n/m 9.71
P/B n/m 5.41 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 3.45 n/m 9.21
Earnings yield (13.50%) (10.96%) (33.15%)
Free cash flow yield (2.38%) (9.41%) (25.50%)

Profitability

Metric NVAX PHVS Biotechnology median
Gross margin 78.60% 0.00% 65.16%
Operating margin (56.58%) 0.00% 0.00%
Net margin (59.87%) 0.00% 0.00%
Free cash flow margin (10.20%) 0.00% 0.00%
Return on equity 323.66% (71.50%) (56.36%)
Return on assets (21.62%) (64.43%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric NVAX PHVS Biotechnology median
Revenue growth (TTM) (61.64%) — 6.02%
EPS growth (last fiscal year) 309.76% (25.37%) 30.26%
Revenue growth, 5-year CAGR 18.76% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NVAX PHVS Biotechnology median
Debt to equity (1.54) 0.00 0.00
Current ratio 2.33 11.94 4.72
Net debt to EBITDA (1.04) 1.72 0.96

Dividend

Metric NVAX PHVS Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric NVAX PHVS Biotechnology median
Market cap 2.11b 2.07b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack